---
title: "Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments"
description: "SciSparc Ltd. has enrolled the first patient in its clinical trial for a CBD-based drug to treat children with autism spectrum disorder. The company plans to enroll 60 participants aged 5 to 18 for a "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/109566212.md"
published_at: "2024-03-08T15:55:52.000Z"
---

# Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments

> SciSparc Ltd. has enrolled the first patient in its clinical trial for a CBD-based drug to treat children with autism spectrum disorder. The company plans to enroll 60 participants aged 5 to 18 for a 20-week trial, comparing the therapy with standard CBD treatment. SciSparc aims to bring the drug to market in Israel initially, with global distribution pending regulatory approvals. Additionally, the company achieved patent approvals in Canada and validation for their core technology patent in 15 European countries.

**SciSparc Ltd.** (NASDAQ:SPRC) announced on Friday that it has **enrolled the first patient** in the company's **clinical trial** assessing the efficacy and safety of its **cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder.**

**SCI-210** is a combination of **CBD and CannAmide** – the company's Palmitoylethanolamide – which is designed to alleviate ASD symptoms.

### Why It Matters

"The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD," said **Oz Adler**, the company's CEO. "We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms.”

The Israel-based SciSparc said it will enroll 60 participants between the ages of 5 and 18, for 20 weeks. The goal of the trial, which is designed in consultation with the National Autism Research Center, is to examine how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD.

The company signed an agreement with Israel’s manufacturer and distributor of cannabis-based products, **Tikun Olam Cannbit Pharmaceuticals Ltd.** (OTC:TKUNF), to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year.

*See also: Cannabis & Children Autism: New Study Claims CBDA Can Help With Behavioral Issues In Kids With ASD*

### What's Next

SciSparc intends to sell SCI-210 in Israel initially with an international drug roll-out subject to obtaining the requisite regulatory approvals**.**

In the meantime, it was a busy week for the Tel Aviv-based company.

### SpiSparc's Recent Milestones

On Wednesday, SpiSparc said in a press release that it had received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment. The patent has been granted by the government agency Canadian Intellectual Property Office.

The company also announced that the process of granting and validating its core technology patent is now completed in 15 European countries. This patent covers combinations of cannabinoids and n-acylethanolamines and aligns with the company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.

*Now read: Cannabis Can Be A Game-Changer For Improving The Lives Of Autistic Adults*

### SPRC Price Action

SciSparc's **shares traded 3.8889% lower at $3.46 per share** at the time of writing on Friday morning.

*The **Benzinga Cannabis Capital Conference** is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at **The Diplomat Beach Resort** will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.*

Get your tickets now on bzcannabis.com – Prices will increase very soon!

### Related Stocks

- [SPRC.US - SciSparc](https://longbridge.com/en/quote/SPRC.US.md)
- [CBDBY.US - Companhia Brasileira De Distribuicao](https://longbridge.com/en/quote/CBDBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 我花了 90 美元進入 JFK Capital One Lounge。是否值得花 395 美元每年辦一張信用卡以獲得無限次進入的資格？ | 一位旅行者為進入 JFK 的 Capital One Lounge 支付了 90 美元，並考慮是否申請 Capital One Venture X 信用卡，該卡每年收費 395 美元，提供無限次的休息室訪問。該卡的優惠包括在前三個月消費 4 | [Link](https://longbridge.com/en/news/276447079.md) |
| 對於傑克丹尼爾的粉絲來説，肯塔基波本威士忌是一個自然的升級選擇 | 傑克丹尼爾（Jack Daniel's）是一款受歡迎的威士忌，但對於那些想嘗試新口味的人來説，梅克爾馬克 46（Maker's Mark 46）是一個很好的替代選擇。它具有更高的酒精度和獨特的陳釀工藝，提供了複雜的風味特徵，包括焦糖、烘焙香 | [Link](https://longbridge.com/en/news/276087148.md) |
| 展望 2026 年駕駛季節，汽油價格的前景如何？ | 2026 年駕駛季節汽油價格的前景如何？ | [Link](https://longbridge.com/en/news/276373094.md) |
| 星巴克股票（SBUX）因在虧損的印度加速門店擴張而失去光彩 | 星巴克（SBUX）股價下跌，因為該公司計劃在印度擴大門店佈局，儘管面臨重大虧損。與塔塔集團的合資企業塔塔星巴克計劃到 2028 年將門店數量從 504 家增加到 1,000 家，同時還將根據當地口味調整菜單。儘管收入同比增長了 7%，但虧損 | [Link](https://longbridge.com/en/news/276447322.md) |
| 以目標為導向的健身：這位 F45 Training 領導者如何身體力行 | 亞德里安·弗米格（Adrian Furminger），F45 Training 亞太區總經理，分享了他從健康危機到領導一個擁有 1500 家全球工作室的健身品牌的旅程。F45 結合了高強度間歇訓練、循環訓練和功能性訓練，課程時長為 45 分 | [Link](https://longbridge.com/en/news/276434353.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
